Alternating regimens in recurrent and metastatic squamous cell carcinoma of the head and neck

F. Cognetti, A. Molinari, P. Carlini, G. L. Frassineti, P. Pinnarò, M. Marangolo

Research output: Contribution to journalArticle

Abstract

In the present pilot study, two courses of CF and CABO combination chemotherapy were administered in an alternating manner to 27 patients affected with recurrent and metastatic squamous cell carcinoma of the head and neck. Of the 23 evaluable patients, 5 complete responses and 5 partial responses were observed; the overall response rate was 43.5%. Two out of five complete responders are still free of disease 30 and 65 weeks after the administration of CR. The toxicity of this program was tolerable and was carried out on an out-patient basis in all cases. The median survival of the entire group was 41 weeks (range 8-98.+). We conclude that these alternating regimens are not likely to produce better responses than other conventional cisplatin-including combinations, but they seems to significantly increase the duration of the response.

Original languageEnglish
Pages (from-to)270-272
Number of pages3
JournalOncology
Volume44
Issue number5
Publication statusPublished - 1987

Fingerprint

Combination Drug Therapy
Cisplatin
Outpatients
Survival
Carcinoma, squamous cell of head and neck

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Alternating regimens in recurrent and metastatic squamous cell carcinoma of the head and neck. / Cognetti, F.; Molinari, A.; Carlini, P.; Frassineti, G. L.; Pinnarò, P.; Marangolo, M.

In: Oncology, Vol. 44, No. 5, 1987, p. 270-272.

Research output: Contribution to journalArticle

@article{61baa2af33044c0c9d84519bf225dedb,
title = "Alternating regimens in recurrent and metastatic squamous cell carcinoma of the head and neck",
abstract = "In the present pilot study, two courses of CF and CABO combination chemotherapy were administered in an alternating manner to 27 patients affected with recurrent and metastatic squamous cell carcinoma of the head and neck. Of the 23 evaluable patients, 5 complete responses and 5 partial responses were observed; the overall response rate was 43.5{\%}. Two out of five complete responders are still free of disease 30 and 65 weeks after the administration of CR. The toxicity of this program was tolerable and was carried out on an out-patient basis in all cases. The median survival of the entire group was 41 weeks (range 8-98.+). We conclude that these alternating regimens are not likely to produce better responses than other conventional cisplatin-including combinations, but they seems to significantly increase the duration of the response.",
author = "F. Cognetti and A. Molinari and P. Carlini and Frassineti, {G. L.} and P. Pinnar{\`o} and M. Marangolo",
year = "1987",
language = "English",
volume = "44",
pages = "270--272",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "5",

}

TY - JOUR

T1 - Alternating regimens in recurrent and metastatic squamous cell carcinoma of the head and neck

AU - Cognetti, F.

AU - Molinari, A.

AU - Carlini, P.

AU - Frassineti, G. L.

AU - Pinnarò, P.

AU - Marangolo, M.

PY - 1987

Y1 - 1987

N2 - In the present pilot study, two courses of CF and CABO combination chemotherapy were administered in an alternating manner to 27 patients affected with recurrent and metastatic squamous cell carcinoma of the head and neck. Of the 23 evaluable patients, 5 complete responses and 5 partial responses were observed; the overall response rate was 43.5%. Two out of five complete responders are still free of disease 30 and 65 weeks after the administration of CR. The toxicity of this program was tolerable and was carried out on an out-patient basis in all cases. The median survival of the entire group was 41 weeks (range 8-98.+). We conclude that these alternating regimens are not likely to produce better responses than other conventional cisplatin-including combinations, but they seems to significantly increase the duration of the response.

AB - In the present pilot study, two courses of CF and CABO combination chemotherapy were administered in an alternating manner to 27 patients affected with recurrent and metastatic squamous cell carcinoma of the head and neck. Of the 23 evaluable patients, 5 complete responses and 5 partial responses were observed; the overall response rate was 43.5%. Two out of five complete responders are still free of disease 30 and 65 weeks after the administration of CR. The toxicity of this program was tolerable and was carried out on an out-patient basis in all cases. The median survival of the entire group was 41 weeks (range 8-98.+). We conclude that these alternating regimens are not likely to produce better responses than other conventional cisplatin-including combinations, but they seems to significantly increase the duration of the response.

UR - http://www.scopus.com/inward/record.url?scp=0023237822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023237822&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 270

EP - 272

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5

ER -